Correlation between thyroid dysfunction and efficacy of immune checkpoint inhibitors in patients with advanced solid tumors

• DOI: 10.1007/s12672-024-01546-4
• Publication Date: 2024-11-16T06:25:51Z
• Authors: Cheng Zhao
• Keywords: Immune checkpoint; Thyroid Dysfunction

Immune checkpoint inhibitors (ICIs) are currently the first line of tumor immunotherapy for treatment a wide range tumors. However, main side effect immune is that they cause immune-related adverse events (irAEs) in patients. The relationship between occurrence effects patients and efficacy controversial. objective this study was to confirm who develop thyroid dysfunction after efficacy. This retrospective real-world clinical study, total 50 with advanced tumors treated at Anqing People's Hospital from 2020.8 2022.5 were retrospectively collected. Among them, 30 hypothyroidism 20 normal or hyperthyroidism occurred, prognostic differences two groups compared. After PD1 all patients, there 10 cases partial remission(PR), 18 stable disease(SD) 2 progressive disease(PD) developed hypothyroidism, disease control rate(DCR) 93.3% remission rate(ORR) 33.3%. There 0 complete (CR) patient, 3 PR 11 SD 6 PD 70.0% DCR 15.0% ORR did not hypothyroidism. better than those non-hypothyroid difference statistically significant (P < 0.05). Kaplan–Meier survival analysis showed progression-free (PFS) reached 9.2 months (95% CI 7.726–10.779) have PFS 7.3 5.604–8.505), = 0.0341 Further subgroup revealed among 3.3 0.630–5.440) cholangiocarcinoma, 6.89 5.604–8.505) non-small cell lung cancer, > 12 hepatocellular carcinoma, 11.05 9.308–12.792) esophageal cancer gastric 9.74 6.979–12.502). When inhibitors, higher had PFS. benefits greater gastric, esophageal, carcinomas.